KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Current Liabilities (2019 - 2025)

Royalty Pharma's Total Current Liabilities history spans 7 years, with the latest figure at $636.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 49.25% year-over-year to $636.2 million; the TTM value through Dec 2025 reached $636.2 million, down 49.25%, while the annual FY2025 figure was $636.2 million, 49.25% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $636.2 million at Royalty Pharma, up from $530.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.3 billion in Q4 2024 and bottomed at $124.6 million in Q1 2024.
  • The 5-year median for Total Current Liabilities is $407.4 million (2021), against an average of $627.0 million.
  • The largest annual shift saw Total Current Liabilities plummeted 88.85% in 2024 before it skyrocketed 849.52% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $171.2 million in 2021, then surged by 581.33% to $1.2 billion in 2022, then crashed by 86.17% to $161.4 million in 2023, then skyrocketed by 676.82% to $1.3 billion in 2024, then tumbled by 49.25% to $636.2 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Total Current Liabilities are $636.2 million (Q4 2025), $530.8 million (Q3 2025), and $1.2 billion (Q2 2025).